The disclosure relates to a pharmaceutical formulation comprising a core comprising hydrocortisone and a carrier and contacting said core a layer comprising a delayed release polymer wherein said delayed release polymer is a pH sensitive enteric polymer and is a mixture of poly (methacrylic acid, methyl methacrylate) in a ratio of 1:1 and poly (methacrylic acid, methyl methacrylate) in a ratio of 1:2 and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.
